Zymeworks Inc.: insider trading
112 trades by 14 directors, officers and 10% owners since 2022, from their SEC Form 4 and 5 filings.
Bought, 12 months
$0
0 purchases by 0 insiders
Sold, 12 months
$6.4 M
15 sales by 6 insiders
Bought, 3 months
$0
0 purchases
Sold, 3 months
$1.8 M
5 sales
Insider buying and selling by month
Open-market purchases and sales by value, last three years.
Insiders (14)
Each insider's latest direct holding and their open-market trades of the last 12 months, most recent first.
| Insider | Shares owned directly | Bought, 12 m | Sold, 12 m | Latest trade |
|---|---|---|---|---|
| Scott PlatshonEVP, Chief Business Officer | 21,745 | — | $382 K | |
| Paul Andrew MooreChief Scientific Officer | 33,756 | — | $1.8 M | |
| Adam SchayowitzEVP, Head of R&D | 23,205 | — | $358 K | |
| Mark HollywoodEVP & Chief Operating Officer | 133,852 | — | $139 K | |
| Jeffrey T. L. SmithEVP & Chief Medical Officer | 26,708 | — | $476 K | |
| Kenneth GalbraithChair & CEO, Director | 226,842 | — | $3.3 M | |
| Leone D. PattersonEVP, Chief Bus & Fin Officer | 459 | — | — | |
| Gregory Austin CiongoliDirector | 488,500 | — | — | |
| Oleg NodelmanDirector, 10% owner | — | — | — | |
| EcoR1 Capital, LLCDirector, 10% owner | — | — | — | |
| Christopher AstleSVP & Chief Financial Officer | 6,503 | — | — | |
| Neil A. KlompasPresident & COO | 17,032 | — | — | |
| Neil JosephsonChief Medical Officer | 14,449 | — | — | |
| Redmile Group, LLC10% owner | — | — | — |
Trades#
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Scott PlatshonEVP, Chief Business Officer | Option exercise | +37,037 | — | — | 37,037 | Form 4 |
| filed | Scott PlatshonEVP, Chief Business Officer | Sell | -15,292 | $24.95 | $382 K | 21,745 | Form 4 |
| filed | Paul Andrew MooreChief Scientific Officer | Option exercise | +25,000 | $5.820 | $146 K | 73,497 | Form 4 |
| filed | Paul Andrew MooreChief Scientific Officer | Sell | -7,367 | $26.14 | $193 K | 66,130 | Form 4 |
| filed | Paul Andrew MooreChief Scientific Officer | Sell | -7,374 | $26.09 | $192 K | 58,756 | Form 4 |
| filed | Paul Andrew MooreChief Scientific Officer | Sell | -25,000 | $26.04 | $651 K | 33,756 | Form 4 |
| filed | Adam SchayowitzEVP, Head of R&D | Option exercise | +37,037 | — | — | 37,037 | Form 4 |
| filed | Adam SchayowitzEVP, Head of R&D | Sell | -13,832 | $25.85 | $358 K | 23,205 | Form 4 |
| filed | Mark HollywoodEVP & Chief Operating Officer | Grant or award | +939 | $22.22 | $21 K | 133,852 | Form 4 |
| filed | Mark HollywoodEVP & Chief Operating Officer | Option exercise | +17,666 | — | — | 139,033 | Form 4 |
| filed | Mark HollywoodEVP & Chief Operating Officer | Sell | -6,120 | $22.67 | $139 K | 132,913 | Form 4 |
| filed | Paul Andrew MooreChief Scientific Officer | Option exercise | +17,666 | — | — | 58,057 | Form 4 |
| filed | Jeffrey T. L. SmithEVP & Chief Medical Officer | Option exercise | +17,666 | — | — | 36,018 | Form 4 |
| filed | Kenneth GalbraithChair & CEO, Director | Option exercise | +64,000 | — | — | 257,266 | Form 4 |
| filed | Jeffrey T. L. SmithEVP & Chief Medical Officer | Sell | -9,310 | $22.67 | $211 K | 26,708 | Form 4 |
| filed | Paul Andrew MooreChief Scientific Officer | Sell | -9,560 | $22.67 | $217 K | 48,497 | Form 4 |
| filed | Kenneth GalbraithChair & CEO, Director | Sell | -30,424 | $22.67 | $690 K | 226,842 | Form 4 |
| filed | Leone D. PattersonEVP, Chief Bus & Fin Officer | Grant or award | +459 | $10.55 | $5 K | 459 | Form 4 |
| filed | Kenneth GalbraithChair & CEO, Director | Option exercise | +47,668 | — | — | 180,943 | Form 4 |
| filed | Jeffrey T. L. SmithEVP & Chief Medical Officer | Option exercise | +20,000 | — | — | 28,890 | Form 4 |
| filed | Paul Andrew MooreChief Scientific Officer | Option exercise | +17,168 | — | — | 40,501 | Form 4 |
| filed | Jeffrey T. L. SmithEVP & Chief Medical Officer | Sell | -10,538 | $25.10 | $265 K | 18,352 | Form 4 |
| filed | Paul Andrew MooreChief Scientific Officer | Sell | -9,289 | $25.10 | $233 K | 31,212 | Form 4 |
| filed | Kenneth GalbraithChair & CEO, Director | Sell | -22,657 | $25.10 | $569 K | 158,286 | Form 4 |
| filed | Paul Andrew MooreChief Scientific Officer | Option exercise | +20,000 | — | — | 51,212 | Form 4 |
| filed | Kenneth GalbraithChair & CEO, Director | Option exercise | +66,666 | — | — | 224,952 | Form 4 |
| filed | Paul Andrew MooreChief Scientific Officer | Sell | -10,821 | $25.10 | $272 K | 40,391 | Form 4 |
| filed | Kenneth GalbraithChair & CEO, Director | Sell | -31,686 | $25.10 | $795 K | 193,266 | Form 4 |
| filed | Kenneth GalbraithChair & CEO, Director | Option exercise | +100,000 | — | — | 180,803 | Form 4 |
| filed | Kenneth GalbraithChair & CEO, Director | Sell | -47,528 | $27.02 | $1.3 M | 133,275 | Form 4 |
| filed | Gregory Austin CiongoliDirector | Grant or award | +415,000 | $12.02 | $5.0 M | 488,500 | Form 4 |
| filed | Oleg NodelmanDirector, 10% owner | Exercise of in-the-money derivativeindirect | +5.09 M | — | — | 22.97 M | Form 4 |
| filed | Oleg NodelmanDirector, 10% owner | Shares withheld for taxindirect | -41 | $12.71 | $521 | 22.97 M | Form 4 |
| filed | EcoR1 Capital, LLCDirector, 10% owner | Buyindirect | +5,919 | $11.78 | $70 K | 17.88 M | Form 4 |
| filed | EcoR1 Capital, LLCDirector, 10% owner | Buyindirect | +49,502 | $11.43 | $566 K | 17.88 M | Form 4 |
| filed | EcoR1 Capital, LLCDirector, 10% owner | Buyindirect | +54,760 | $11.52 | $631 K | 17.83 M | Form 4 |
| filed | EcoR1 Capital, LLCDirector, 10% owner | Buyindirect | +73,953 | $11.16 | $825 K | 17.77 M | Form 4 |
| filed | Oleg NodelmanDirector, 10% owner | Buyindirect | +196,438 | $11.17 | $2.2 M | 17.70 M | Form 4 |
| filed | Oleg NodelmanDirector, 10% owner | Buyindirect | +120,770 | $11.84 | $1.4 M | 17.50 M | Form 4 |
| filed | EcoR1 Capital, LLCDirector, 10% owner | Buyindirect | +74,360 | $11.85 | $881 K | 17.38 M | Form 4 |
| filed | EcoR1 Capital, LLCDirector, 10% owner | Buyindirect | +48,658 | $11.60 | $564 K | 17.31 M | Form 4 |
| filed | EcoR1 Capital, LLCDirector, 10% owner | Buyindirect | +4,397 | $11.75 | $52 K | 17.26 M | Form 4 |
| filed | EcoR1 Capital, LLCDirector, 10% owner | Buyindirect | +43,848 | $12.24 | $537 K | 17.26 M | Form 4 |
| filed | EcoR1 Capital, LLCDirector, 10% owner | Buyindirect | +53,501 | $12.91 | $691 K | 17.21 M | Form 4 |
| filed | EcoR1 Capital, LLCDirector, 10% owner | Buyindirect | +22,689 | $13.08 | $297 K | 17.16 M | Form 4 |
| filed | EcoR1 Capital, LLCDirector, 10% owner | Buyindirect | +31,033 | $12.78 | $397 K | 17.14 M | Form 4 |
| filed | EcoR1 Capital, LLCDirector, 10% owner | Buyindirect | +73,476 | $12.93 | $950 K | 17.10 M | Form 4 |
| filed | EcoR1 Capital, LLCDirector, 10% owner | Buyindirect | +58,306 | $12.64 | $737 K | 17.03 M | Form 4 |
| filed | EcoR1 Capital, LLCDirector, 10% owner | Buyindirect | +113,880 | $12.65 | $1.4 M | 16.97 M | Form 4 |
| filed | EcoR1 Capital, LLCDirector, 10% owner | Buyindirect | +56,277 | $12.23 | $688 K | 16.86 M | Form 4 |
| filed | Oleg NodelmanDirector, 10% owner | Buyindirect | +468,356 | $12.48 | $5.8 M | 16.80 M | Form 4 |
| filed | Oleg NodelmanDirector, 10% owner | Buyindirect | +292,934 | $12.25 | $3.6 M | 16.33 M | Form 4 |
| filed | Oleg NodelmanDirector, 10% owner | Buyindirect | +320,690 | $11.49 | $3.7 M | 16.04 M | Form 4 |
| filed | EcoR1 Capital, LLCDirector, 10% owner | Buyindirect | +19,748 | $13.87 | $274 K | 15.72 M | Form 4 |
| filed | EcoR1 Capital, LLCDirector, 10% owner | Buyindirect | +121,681 | $13.89 | $1.7 M | 15.70 M | Form 4 |
| filed | EcoR1 Capital, LLCDirector, 10% owner | Buyindirect | +39,029 | $14.01 | $547 K | 15.58 M | Form 4 |
| filed | EcoR1 Capital, LLCDirector, 10% owner | Buyindirect | +54,500 | $13.56 | $739 K | 15.54 M | Form 4 |
| filed | EcoR1 Capital, LLCDirector, 10% owner | Buyindirect | +74,125 | $13.39 | $993 K | 15.49 M | Form 4 |
| filed | EcoR1 Capital, LLCDirector, 10% owner | Buyindirect | +204,098 | $13.13 | $2.7 M | 15.41 M | Form 4 |
| filed | EcoR1 Capital, LLCDirector, 10% owner | Buyindirect | +21,021 | $14.07 | $296 K | 15.21 M | Form 4 |
| filed | Jeffrey T. L. SmithEVP & Chief Medical Officer | Option exercise | +20,000 | — | — | 20,000 | Form 4 |
| filed | Kenneth GalbraithChair & CEO, Director | Option exercise | +47,666 | — | — | 71,428 | Form 4 |
| filed | Paul Andrew MooreChief Scientific Officer | Option exercise | +17,166 | — | — | 24,533 | Form 4 |
| filed | Jeffrey T. L. SmithEVP & Chief Medical Officer | Sell | -11,110 | $14.92 | $166 K | 8,890 | Form 4 |
| filed | Paul Andrew MooreChief Scientific Officer | Sell | -9,792 | $14.92 | $146 K | 14,741 | Form 4 |
| filed | Kenneth GalbraithChair & CEO, Director | Sell | -23,885 | $14.92 | $356 K | 47,543 | Form 4 |
| filed | Paul Andrew MooreChief Scientific Officer | Option exercise | +20,000 | — | — | 34,741 | Form 4 |
| filed | Kenneth GalbraithChair & CEO, Director | Option exercise | +66,666 | — | — | 114,209 | Form 4 |
| filed | Kenneth GalbraithChair & CEO, Director | Sell | -33,406 | $14.92 | $498 K | 80,803 | Form 4 |
| filed | Paul Andrew MooreChief Scientific Officer | Sell | -11,408 | $14.92 | $170 K | 23,333 | Form 4 |
| filed | EcoR1 Capital, LLCDirector, 10% owner | Buyindirect | +157,880 | $14.78 | $2.3 M | 15.19 M | Form 4 |
| filed | EcoR1 Capital, LLCDirector, 10% owner | Buyindirect | +146,501 | $14.57 | $2.1 M | 15.03 M | Form 4 |
| filed | EcoR1 Capital, LLCDirector, 10% owner | Buyindirect | +58,988 | $14.47 | $854 K | 14.88 M | Form 4 |
| filed | EcoR1 Capital, LLCDirector, 10% owner | Buyindirect | +101,659 | $14.49 | $1.5 M | 14.82 M | Form 4 |
| filed | EcoR1 Capital, LLCDirector, 10% owner | Buyindirect | +16,692 | $14.38 | $240 K | 14.72 M | Form 4 |
| filed | EcoR1 Capital, LLCDirector, 10% owner | Buyindirect | +11,958 | $14.12 | $169 K | 14.70 M | Form 4 |
| filed | EcoR1 Capital, LLCDirector, 10% owner | Buyindirect · amended | +251,502 | $14.25 | $3.6 M | 14.69 M | Form 4/A |
| filed | EcoR1 Capital, LLCDirector, 10% owner | Buyindirect · amended | +704,488 | $14.08 | $9.9 M | 14.44 M | Form 4/A |
| filed | EcoR1 Capital, LLCDirector, 10% owner | Buyindirect · amended | +298,818 | $13.53 | $4.0 M | 13.74 M | Form 4/A |
| filed | Paul Andrew MooreChief Scientific Officer | Sell | -2,339 | $11.22 | $26 K | 7,367 | Form 4 |
| filed | Christopher AstleSVP & Chief Financial Officer | Sell | -1,431 | $11.22 | $16 K | 6,503 | Form 4 |
| filed | Kenneth GalbraithChair & CEO, Director | Sell | -5,706 | $11.22 | $64 K | 23,762 | Form 4 |
| filed | Kenneth GalbraithChair & CEO, Director | Option exercise | +47,666 | — | — | 47,666 | Form 4 |
| filed | Paul Andrew MooreChief Scientific Officer | Option exercise | +17,166 | — | — | 17,166 | Form 4 |
| filed | Christopher AstleSVP & Chief Financial Officer | Option exercise | +10,500 | — | — | 12,497 | Form 4 |
| filed | Christopher AstleSVP & Chief Financial Officer | Sell | -4,563 | $10.65 | $49 K | 7,934 | Form 4 |
| filed | Paul Andrew MooreChief Scientific Officer | Sell | -7,460 | $10.65 | $79 K | 9,706 | Form 4 |
| filed | Kenneth GalbraithChair & CEO, Director | Sell | -18,198 | $10.65 | $194 K | 29,468 | Form 4 |
| filed | Christopher AstleSVP & Chief Financial Officer | Option exercise | +1,550 | — | — | 2,883 | Form 4 |
| filed | Christopher AstleSVP & Chief Financial Officer | Sell | -886 | $9.130 | $8 K | 1,997 | Form 4 |
| filed | EcoR1 Capital, LLC10% owner | Buyindirect | +3.35 M | $8.120 | $27.2 M | 13.44 M | Form 4 |
| filed | EcoR1 Capital, LLC10% owner | Buyindirect | +200,000 | $8.000 | $1.6 M | 10.09 M | Form 4 |
| filed | Neil A. KlompasPresident & COO | Option exercise | +2,500 | — | — | 17,301 | Form 4 |
| filed | Neil A. KlompasPresident & COO | Option exercise | +2,708 | — | — | 20,009 | Form 4 |
| filed | Neil A. KlompasPresident & COO | Sell | -2,977 | $7.830 | $23 K | 17,032 | Form 4 |
| filed | EcoR1 Capital, LLC10% owner | Buyindirect | +163,400 | $9.880 | $1.6 M | 9.89 M | Form 4 |
| filed | EcoR1 Capital, LLC10% owner | Buyindirect | +144,100 | $9.490 | $1.4 M | 9.72 M | Form 4 |
| filed | EcoR1 Capital, LLC10% owner | Buyindirect | +203,000 | $10.00 | $2.0 M | 9.58 M | Form 4 |
| filed | EcoR1 Capital, LLC10% owner | Buyindirect | +440,000 | $9.800 | $4.3 M | 9.38 M | Form 4 |
| filed | EcoR1 Capital, LLC10% owner | Buyindirect | +342,100 | $9.810 | $3.4 M | 8.94 M | Form 4 |
| filed | EcoR1 Capital, LLC10% owner | Buyindirect | +106,300 | $7.870 | $837 K | 8.59 M | Form 4 |
| filed | EcoR1 Capital, LLC10% owner | Buyindirect | +920,000 | $7.650 | $7.0 M | 8.49 M | Form 4 |
| filed | Christopher AstleSVP & Chief Financial Officer | Option exerciseamended | +1,550 | — | — | 2,220 | Form 4/A |
| filed | Christopher AstleSVP & Chief Financial Officer | Sell10b5-1 plan · amended | -887 | $6.010 | $5 K | 1,333 | Form 4/A |
| filed | Christopher AstleSVP & Chief Financial Officer | Option exercise | +1,550 | — | — | 2,220 | Form 4 |
| filed | Christopher AstleSVP & Chief Financial Officer | Sell10b5-1 plan | -887 | $6.010 | $5 K | 1,333 | Form 4 |
| filed | Neil JosephsonChief Medical Officer | Option exerciseamended | +5,885 | — | — | 16,924 | Form 4/A |
| filed | Neil JosephsonChief Medical Officer | Sell10b5-1 plan · amended | -2,475 | $8.100 | $20 K | 14,449 | Form 4/A |
| filed | Neil JosephsonChief Medical Officer | Option exercise | +5,885 | — | — | 16,924 | Form 4 |
| filed | Neil JosephsonChief Medical Officer | Sell10b5-1 plan | -2,475 | $8.100 | $20 K | 14,449 | Form 4 |
| filed | Redmile Group, LLC10% owner | Buyindirect · amended | +30,481 | $5.030 | $153 K | 6.08 M | Form 4/A |
| filed | Redmile Group, LLC10% owner | Grant or awardindirect | +30,481 | $5.030 | $153 K | 6.08 M | Form 4 |
Source: SEC Forms 4 and 5. A trade under a 10b5-1 plan was scheduled in advance. For information only; not investment advice